Skip to main content
SpringerLink
Log in

Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension

  • Letter To The Editor
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gallotti R, Drogalis-Kim DE, Satou G, Alejos J (2017) Single-center experience using selexipag in a pediatric population. Pediatr Cardiol. doi:10.1007/s00246-017-1677-7

    PubMed  Google Scholar 

  2. Hansmann G, Apitz C (2016) Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii67–85

    Article  CAS  PubMed  Google Scholar 

  3. Ewert R, Richter MJ, Steringer-Mascherbauer R, Grünig E, Lange TJ, Opitz CF et al (2017) Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clin Res Cardiol. doi:10.1007/s00392-017-1114-1

    Google Scholar 

  4. Geerdink LM, Bertram H, Hansmann G (2017) First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulm Circ 7:551–554

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hansmann G, Apitz C (2016) The need for comprehensive cardiac catheterization in children with pulmonary hypertension. J Am Coll Cardiol 67:1009–1010

    Article  PubMed  Google Scholar 

  6. Hansmann G (2017) Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol 69:2551–2569

    Article  PubMed  Google Scholar 

  7. Koestenberger M, Apitz C, Abdul-Khaliq H, Hansmann G (2016) Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii14–22

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Cardiology, Department of Pediatrics, Medical University Graz, Graz, Austria

    Martin Koestenberger

  2. Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Georg Hansmann

Authors
  1. Martin Koestenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Hansmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Hansmann.

Ethics declarations

Confilct of interest

The authors declare that there was no financial support that might pose a conflict of interest in connection with the submitted article.

Research Involving Human and Animal Participants

This letter does not include any research involving human participants and/or animals.

Informed Consent

Informed consent has not been obtained as such consent is not applicable for this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koestenberger, M., Hansmann, G. Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension. Pediatr Cardiol 38, 1523–1524 (2017). https://doi.org/10.1007/s00246-017-1699-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-017-1699-1

Search

Navigation